312 related articles for article (PubMed ID: 28483412)
1. Cancer Drugs Fund of minimal benefit.
Burki TK
Lancet Oncol; 2017 Jun; 18(6):e305. PubMed ID: 28483412
[No Abstract] [Full Text] [Related]
2. New NICE criteria for drug access.
Fricker J
Lancet Oncol; 2017 May; 18(5):576. PubMed ID: 28343973
[No Abstract] [Full Text] [Related]
3. Health policy: Putting a price on cancer.
Sullivan R; Aggarwal A
Nat Rev Clin Oncol; 2016 Mar; 13(3):137-8. PubMed ID: 26856742
[No Abstract] [Full Text] [Related]
4. Pfizer to make palbociclib temporarily free on NHS.
Burki TK
Lancet Oncol; 2017 Jun; 18(6):e309. PubMed ID: 28506556
[No Abstract] [Full Text] [Related]
5. UK Cancer Drugs Fund to reassess 42 agents.
Cagney H
Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638560
[No Abstract] [Full Text] [Related]
6. NHS will not pay for drugs that offer little clinical benefit, says cancer fund boss.
Kmietowicz Z
BMJ; 2015 Jan; 350():h125. PubMed ID: 25569117
[No Abstract] [Full Text] [Related]
7. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
Low E;
J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
[No Abstract] [Full Text] [Related]
8. Most drugs paid for by £1.27bn Cancer Drugs Fund had no "meaningful benefit".
Cohen D
BMJ; 2017 Apr; 357():j2097. PubMed ID: 28455308
[No Abstract] [Full Text] [Related]
9. A question of health. The lottery of cancer care.
Health Serv J; 1997 Dec; 107(5584):suppl 1-4 following 24. PubMed ID: 10184833
[No Abstract] [Full Text] [Related]
10. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
Prasad V; Mailankody S
Mayo Clin Proc; 2016 Jun; 91(6):707-12. PubMed ID: 27261866
[No Abstract] [Full Text] [Related]
11. Reforming the cancer drug fund.
Buxton M; Longworth L; Raftery J; Sculpher M; Towse A
BMJ; 2014 Nov; 349():g7276. PubMed ID: 25432928
[No Abstract] [Full Text] [Related]
12. MPs find no evidence that Cancer Drugs Fund was spent wisely.
Hawkes N
BMJ; 2016 Feb; 352():i755. PubMed ID: 26850036
[No Abstract] [Full Text] [Related]
13. NICE, the NHS, and Cancer Drugs.
Dillon A; Landells LJ
JAMA; 2018 Feb; 319(8):767-768. PubMed ID: 29387883
[No Abstract] [Full Text] [Related]
14. New "managed access" process for Cancer Drugs Fund to go ahead, NHS England confirms.
Mayor S
BMJ; 2016 Feb; 352():i1208. PubMed ID: 26926879
[No Abstract] [Full Text] [Related]
15. Unfunded promises as the UK health debate takes centre stage.
Lancet Oncol; 2010 May; 11(5):401. PubMed ID: 20409754
[No Abstract] [Full Text] [Related]
16. Japanese universal health care faces a crisis in cancer treatment.
Fujiwara Y; Yonemori K; Shibata T; Okita N; Ushirozawa N
Lancet Oncol; 2015 Mar; 16(3):251-2. PubMed ID: 25752548
[No Abstract] [Full Text] [Related]
17. UK Government urged to recognise post-COVID-19 cancer backlog.
Wilkinson E
Lancet Oncol; 2021 Jul; 22(7):910. PubMed ID: 34090554
[No Abstract] [Full Text] [Related]
18. Cost to the NHS of Roche oncology treatments.
Atkins M
J R Soc Med; 2007 Jul; 100(7):303. PubMed ID: 17606744
[No Abstract] [Full Text] [Related]
19. Perspectives on Cost and Value in Cancer Care.
Saltz LB
JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
[No Abstract] [Full Text] [Related]
20. Careful use of science to advance the debate on the UK Cancer Drugs Fund.
Lakdawalla DN; Jena AB; Doctor JN
JAMA; 2014 Jan; 311(1):25-6. PubMed ID: 24381964
[No Abstract] [Full Text] [Related]
[Next] [New Search]
